← Back to patent-cliff list
CAS 694499-26-8
4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline
Codes: HQP-1351-002
Application context (from source-drug indications)
Chronic myeloid leukaemiaOlverembatinib髓系白血病加速期OlverembatinibGastrointestinal stromal tumourOlverembatinibMyeloid leukaemiaOlverembatinibLymphocytic leukaemiaOlverembatinibAcute lymphoblastic leukaemiaOlverembatinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Olverembatinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
methyl 3-iodo-4-methylbenzoate→4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline→3-iodo-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide→HQP-1351-004→HQP-1351-005→HQP-1351
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 4-(4-Methylpiperazin-1-ylmethyl)-3-trifluoromethylaniline Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.